Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 752.60, up by 8.70 points or 1.17% from its previous closing of Rs. 743.90 on the BSE.

The scrip opened at Rs. 751.00 and has touched a high and low of Rs. 757.50 and Rs. 745.75 respectively. So far 23248 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 757.50 on 22-Jul-2014 and a 52 week low of Rs. 475.60 on 22-Aug-2013.

Last one week high and low of the scrip stood at Rs. 753.65 and Rs. 733.00 respectively. The current market cap of the company is Rs. 155969.00 crore.

The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 28.05% and 8.29% respectively.

The two leading stock exchanges -- BSE and NSE -- have given clearance to $4-billion merger of Ranbaxy Laboratories with Sun Pharmaceutical Industries. The ‘no-objection’ from the two exchanges would allow both the entities to file their scheme of amalgamation with the High Court for further clearance of the deal and marks one of the numerous regulatory approvals that Sun Pharma and Ranbaxy need to consummate for the transaction.

The deal had separately come under scanner of the markets regulator SEBI for alleged insider trading violations and the present ‘no-objection’ from the exchanges.

The combination of Sun Pharma and Ranbaxy creates the fifth-largest speciality generics company in the world and the largest pharmaceutical company in India. The two firms now need clearances of the High Court and the Competition Commission of India (CCI), among others.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.